ArticleCureus2025
A Comparative Evaluation of the Effects of Saroglitazar and Pioglitazone on Hepatic and Metabolic Parameters in Type 2 Diabetes Mellitus With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Type 2 diabetes mellitus (T2DM) is frequently accompanied by metabolic dysfunction-associated steatotic liver disease (MASLD), compounding morbidity and mortality risks. Pharmacologic strategies that directly target hepatic steatosis and fibrosis in this population remain limited. Saroglitazar, a dual PPARα/γ agonist, and pioglitazone, a proliferator-activated receptor gamma (PPAR-γ) agonist, may offer potential benefits. This study aimed to compare their effects on hepatic, glycemic, and metabolic parameters in patients with T2DM and MASLD. Methods In this study, 96 adults with T2DM and MASLD were randomized to receive either pioglitazone 15 mg or saroglitazar 4 mg daily for 12 months. Primary outcomes included changes in the non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS), liver stiffness measurement (LSM), and controlled attenuation parameter (CAP). Secondary outcomes assessed fasting plasma glucose (FPG), postprandial glucose (PPPG), HbA1c, lipid profile, triglyceride-glucose (TyG) index, and BMI. Assessments were performed at baseline and at three, six, and 12 months. Data were analyzed using paired and unpaired t-tests. Results Saroglitazar produced a significant reduction in NFS (-0.57, p = 0.026) and a non-significant decrease in LSM (-1.1 kPa). CAP declined by 18.6 dB/m (p = 0.059). HbA1c dropped by 0.81% (p<0.0001) with saroglitazar, surpassing pioglitazone's 0.31% reduction. Both groups showed modest improvements in lipid levels and stable TyG indices. Saroglitazar led to a significant BMI reduction (-3.32 kg/m², p = 0.006); pioglitazone showed no BMI change. Both treatments were well tolerated, with no major adverse events reported. Conclusions Saroglitazar demonstrated superior benefits over pioglitazone in improving hepatic steatosis and fibrosis, glycemic control, and BMI in patients with T2DM and MASLD, while maintaining a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.